摘要： 心力衰竭是一种高患病率和高病死率的临床综合征。虽然药物治疗是基础,但对改善患者长期预后和生活质量仍存在明显的局限性。近年来,运动康复联合药物治疗的干预模式在心力衰竭管理中展现出显著的优势,如改善患者的运动能力、生活质量和心功能指标等。该文围绕运动康复与药物联合治疗心力衰竭的协同作用及机制进行综述,旨在为心力衰竭的综合管理策略提供理论依据和实践指导。
陈巧莹, 彭燕燕. 运动康复联合药物治疗心力衰竭的研究进展[J]. 心血管病防治知识, 2026, 16(9): 138-144.
| [1] Bozkurt B, Coats AJS, Tsutsui H, et al.Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association[J]. Eur J Heart Fail, 2021, 23(3):352-380. [2] Heidenreich PA, Bozkurt B, Aguilar D, et al.2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. Circulation, 2022, 145(18):e895-e1032. [3] Zhang SY.Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024[J]. J Geriatr Cardiol, 2025, 22(3):277-331. [4] 国家卫生健康委员会. 中国卫生健康统计年鉴2023[M], 2024年8月第1版. 北京, 中国协和医科大学出版社, 2024: 119-178. [5] Diseases NCfC, Health TWCotRoC, China Di. Report on Cardiovascular Health and Diseases in China 2024: an Updated Summary[J]. Chinese Circulation Journal, 2025, 40(6):521-559. [6] Luo HZ, Ren N, Hong W, et al.Clinical Study on Chronic Heart Failure with Drugs Combined with Heart Rehabilitation[J]. Chinese and Foreign Medical Research, 2020, 18(28):4-6. [7] Packer M.The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure[J]. J Am Coll Cardiol, 1992, 20(1):248-254. [8] Hartupee J, Mann DL.Neurohormonal activation in heart failure with reduced ejection fraction[J]. Nature Reviews Cardiology, 2017, 14(1):30-38. [9] Krack A, Sharma R, Figulla HR, et al.The importance of the gastrointestinal system in the pathogenesis of heart failure[J]. Eur Heart J, 2005, 26(22):2368-2374. [10] Li X, Geng J, Zhao J, et al.Trimethylamine N-Oxide Exacerbates Cardiac Fibrosis via Activating the NLRP3 Inflammasome[J]. Front Physiol, 2019, 10:866. [11] Bozkurt B, Fonarow GC, Goldberg LR, et al.Cardiac Rehabilitation for Patients With Heart Failure: JACC Expert Panel[J]. J Am Coll Cardiol, 2021, 77(11):1454-1469. [12] Chen J, Jia S, Xue X, et al.Gut microbiota: a novel target for exercise-mediated regulation of NLRP3 inflammasome activation[J]. Front Microbiol, 2024, 15:1476908. [13] Beavers KM, Brinkley TE, Nicklas BJ.Effect of exercise training on chronic inflammation[J]. Clin Chim Acta, 2010, 411(11-12):785-793. [14] Ritchey MD, Maresh S, McNeely J, et al. Tracking Cardiac Rehabilitation Participation and Completion Among Medicare Beneficiaries to Inform the Efforts of a National Initiative[J]. Circ Cardiovasc Qual Outcomes, 2020, 13(1):e005902. [15] Wang Z, Ma L, Liu M, et al.Summary of the 2022 Report on Cardiovascular Health and Diseases in China[J]. Chin Med J (Engl), 2023, 136(24):2899-2908. [16] Zhang BY, Bai XL, Yang ZZ, et al.Research Progress on the Current Status and Influencing Factors of Exercise Rehabilitation in Patients with Chronic Heart Failure[J]. Pract J Cardiac Cereb Pneum Vasc Dis, 2025, 33(5):41-45. [17] Coats AJS, Tolppanen H.Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat[J]. Drugs, 2021, 81(14):1599-1604. [18] Marti CN, Gheorghiade M, Kalogeropoulos AP, et al.Endothelial dysfunction, arterial stiffness, and heart failure[J]. J Am Coll Cardiol, 2012, 60(16):1455-1469. [19] Hubers SA, Brown NJ.Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition[J]. Circulation, 2016, 133(11):1115-1124. [20] Mousa TM, Liu D, Cornish KG, et al.Exercise training enhances baroreflex sensitivity by an angiotensin II-dependent mechanism in chronic heart failure[J]. J Appl Physiol (1985), 2008, 104(3):616-624. [21] Su H, Zhu J, Wang GY.Application effect of Sacubitril Valsartan and cardiac rehabilitation therapy in patients with heart failure[J]. China Modern Medicine, 2022, 29(16):103-106,110. [22] Azevedo ER, Kubo T, Mak S, et al.Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity[J]. Circulation, 2001, 104(18):2194-2199. [23] Ichige MH, Santos CR, Jordão CP, et al.Exercise training preserves vagal preganglionic neurones and restores parasympathetic tonus in heart failure[J]. J Physiol, 2016, 594(21):6241-6254. [24] [25] 张杰. 康复运动对慢性心力衰竭患者心脏自主神经功能及运动耐量的影响[J]. 中国疗养医学, 2020, 29(3):263-265. [26] Mittal M, Siddiqui MR, Tran K, et al.Reactive oxygen species in inflammation and tissue injury[J]. Antioxid Redox Signal, 2014, 20(7):1126-1167. [27] Kolijn D, Pabel S, Tian Y, et al.Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation[J]. Cardiovasc Res, 2021, 117(2):495-507. [28] de Meirelles LR, Matsuura C, Resende Ade C, et al. Chronic exercise leads to antiaggregant, antioxidant and anti-inflammatory effects in heart failure patients[J]. Eur J Prev Cardiol, 2014, 21(10):1225-1232. [29] Wang X, Yan K, Wen C, et al.Simvastatin Combined with Resistance Training Improves Outcomes in Patients with Chronic Heart Failure by Modulating Mitochondrial Membrane Potential and the Janus Kinase/Signal Transducer and Activator of Transcription 3 Signaling Pathways[J]. Cardiovasc Ther, 2022, 2022:8430733. [30] Travers JG, Kamal FA, Robbins J, et al.Cardiac Fibrosis: The Fibroblast Awakens[J]. Circ Res, 2016, 118(6):1021-1040. [31] Daud E, Ertracht O, Bandel N, et al.The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats[J]. Cardiovasc Diabetol, 2021, 20(1):132. [32] Sun G, Tong S, Li H, et al.Efficacy of Vericiguat in the Treatment of Elderly Patients with HF and Its Impact on The TGF-β1/Smad3 Signaling Pathway and Rehospitalization Rate[J]. Translational Medicine Journal, 2025, 14(3):103-109. [33] Zhu Y, Zhang F, Li Z, et al.Chinese and western medicine treatment of myocardial fibrosis drugs[J]. Front Cardiovasc Med, 2024, 11:1477601. [34] Ma Y, Kuang Y, Bo W, et al.Exercise Training Alleviates Cardiac Fibrosis through Increasing Fibroblast Growth Factor 21 and Regulating TGF-β1-Smad2/3-MMP2/9 Signaling in Mice with Myocardial Infarction[J]. Int J Mol Sci, 2021, 22(22). [35] 王建美, 金卫东, 韩明磊. 运动康复训练对冠心病慢性心衰患者的影响[J]. 实用中西医结合临床, 2021, 21(6):59-60. [36] Mammi C, la Sala A, Volterrani M, et al. Exercise training reduces serum capacity to induce endothelial cell death in patients with chronic heart failure[J]. Eur J Heart Fail, 2011, 13(6):642-650. [37] Li H, Zhang Y, Ma J.Effects of yiqi huoxue compound combined with exercise therapy on MMP-1 and collagen type III expressions of cardiac muscle in chronic heart failure rats[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2011, 31(7):955-960. [38] Varin R, Mulder P, Richard V, et al.Exercise improves flow-mediated vasodilatation of skelet al muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress[J]. Circulation, 1999, 99(22):2951-2957. [39] Zhang N, Feng B, Ma X, et al.Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol, 2019, 18(1):107. [40] Ilonze OJ, Forman DE, LeMond L, et al. Beyond Guideline-Directed Medical Therapy: Nonpharmacologic Management for Patients With Heart Failure[J]. JACC Heart Fail, 2025, 13(2):185-199. [41] Tucker WJ, Beaudry RI, Liang Y, et al.Meta-analysis of Exercise Training on Left Ventricular Ejection Fraction in Heart Failure with Reduced Ejection Fraction: A 10-year Update[J]. Prog Cardiovasc Dis, 2019, 62(2):163-171. [42] McDonagh TA, Metra M, Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J, 2021, 42(36):3599-3726. [43] Association PCoCPaRoCRM. Expert consensus on cardiac rehabilitation for chronic heart failure in China[J]. Chin J Intern Med, 2020, 59(12):942-952. [44] Franklin BA, Thompson PD, Al-Zaiti SS, et al.Exercise-Related Acute Cardiovascular Events and Potential Deleterious Adaptations Following Long-Term Exercise Training: Placing the Risks Into Perspective-An Update: A Scientific Statement From the American Heart Association[J]. Circulation, 2020, 141(13):e705-e736. [45] Mueller S, Winzer EB, Duvinage A, et al.Effect of High-Intensity Interval Training, Moderate Continuous Training, or Guideline-Based Physical Activity Advice on Peak Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial[J]. Jama, 2021, 325(6):542-551. [46] Pandey A, Parashar A, Kumbhani D, et al.Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials[J]. Circ Heart Fail, 2015, 8(1):33-40. [47] Crisci G, De Luca M, D'Assante R, et al. Effects of Exercise on Heart Failure with Preserved Ejection Fraction: An Updated Review of Literature[J]. J Cardiovasc Dev Dis, 2022, 9(8). [48] Redfield MM, Borlaug BA.Heart Failure With Preserved Ejection Fraction: A Review[J]. Jama, 2023, 329(10):827-838. |
| [1] | 温国河. 非奈利酮片治疗射血分数降低型心力衰竭的临床效果[J]. 心血管病防治知识, 2026, 16(9): 3-6. |
| [2] | 梁幼斌, 陈焕平. 苓桂术甘汤合参附汤加减在急性心力衰竭伴心房颤动水饮凌心证患者中的应用效果[J]. 心血管病防治知识, 2026, 16(9): 32-36. |
| [3] | 黄雁玲, 郭毅斌. 幸福PERMA模式下代谢当量运动康复护理联合心理护理在老年冠心病患者中的应用[J]. 心血管病防治知识, 2026, 16(9): 50-53. |
| [4] | 农志林. 延伸护理服务模式在预见性评估慢性心力衰竭患者生活质量和预后中的应用价值[J]. 心血管病防治知识, 2026, 16(9): 73-76. |
| [5] | 陈菲, 陈茜茜, 杨露. 家庭赋能干预对老年心力衰竭患者照顾负担及预后的影响[J]. 心血管病防治知识, 2026, 16(9): 77-81. |
| [6] | 梁晓华. 慢性心力衰竭患者健康行为信息框架效应干预方案构建及应用[J]. 心血管病防治知识, 2026, 16(9): 82-86. |
| [7] | 车阿明, 俞佳丽, 钱佳雯. 不同疗程重组人脑利钠肽治疗急性ST段抬高型心肌梗死后并发心力衰竭的效果及机制分析[J]. 心血管病防治知识, 2026, 16(8): 6-8. |
| [8] | 赵敏, 冯洁, 高金宝. 维立西呱联合标准治疗方案治疗射血分数降低心力衰竭的药物经济学分析[J]. 心血管病防治知识, 2026, 16(8): 21-24. |
| [9] | 彭云华, 陈华, 黄仲伟. NT-proBNP和ALP联合尿mAlb对急性失代偿性心力衰竭患者肾功能恶化的预测价值[J]. 心血管病防治知识, 2026, 16(8): 32-36. |
| [10] | 王建宇, 刘雯雯, 朱君君, 王明雅, 高小芳. 左西孟旦联合多巴酚丁胺对顽固性急性心力衰竭患者心排血指数及肺动脉楔压改善的作用分析[J]. 心血管病防治知识, 2026, 16(8): 37-40. |
| [11] | 黄雁玲, 郭毅斌. 运动康复护理联合营养处方干预对老年冠心病患者生活质量改善研究[J]. 心血管病防治知识, 2026, 16(8): 70-72. |
| [12] | 魏小兰, 邱模丽, 陆传玉. 基于授权理论的容量管理在慢性心力衰竭患者中的应用效果[J]. 心血管病防治知识, 2026, 16(8): 90-93. |
| [13] | 张宇杰, 何沛沛. 老年慢性心力衰竭患者治疗负担潜在剖面及其与衰弱的相关性[J]. 心血管病防治知识, 2026, 16(8): 94-100. |
| [14] | 张勇平. 心力衰竭患者BMI分层与长期生存预后的关联研究[J]. 心血管病防治知识, 2026, 16(7): 3-6. |
| [15] | 袁敏, 张其银, 王志松. apoA1联合Trx-1对急性心力衰竭患者预后的预测价值分析[J]. 心血管病防治知识, 2026, 16(7): 32-35. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
